EXHIBIT 99.2


 FOR IMMEDIATE RELEASE

 Media Contact:
 Carol Goodrich, (973) 540-3620     Investor Relations Contacts:
                                    George Shields, (973) 540-6916
                                    John Howarth, (973) 540-4874


                 WARNER-LAMBERT FILES CLAIM AGAINST PFIZER
                        TO END LIPITOR(R) AGREEMENTS

         SEEKS TO RECLAIM FULL VALUE OF LIPITOR(R) FOR SHAREHOLDERS
                  MASSIVE AND INTENTIONAL BREACHES ALLEGED

 MORRIS PLAINS, N.J., November. 29, 1999 -- Warner-Lambert Company (NYSE:
 WLA) today announced that, as a result of massive and intentional breaches
 by Pfizer Inc. of Warner-Lambert's agreements with Pfizer relating to
 Lipitor(R), Warner-Lambert has filed a counterclaim against Pfizer seeking
 a declaratory judgment that Warner-Lambert is entitled to terminate the
 Lipitor(R) agreements.

 "We are asking the court to confirm that Pfizer's intentional disregard of
 its contractual obligations has given us the right to bring this
 relationship to an end and reclaim all rights to Lipitor(R) for
 Warner-Lambert and our shareholders.  Sales of Lipitor(R) are expected to
 surpass $3.6 billion in 1999.  Pfizer cannot commit flagrant breaches of
 contract, as it has, and expect to continue to receive the fruits of this
 relationship," said Lodewijk J.R. de Vink, chairman, president and chief
 executive officer of Warner-Lambert.

 The counterclaim sets forth that Pfizer has repeatedly misstated the terms
 of the standstill restrictions to which it agreed in the Lipitor(R)
 agreements.  The actual language of the standstill makes clear, and the
 counterclaim sets forth, that Pfizer breached its agreement when it made
 its November 4, 1999 proposal for Warner-Lambert and in its subsequent
 actions.

 Pfizer has asserted that the standstill provisions terminated when
 Warner-Lambert entered into its merger-of-equals transaction with American
 Home Products. Pfizer is wrong.  The standstill provisions expressly
 provide that they terminate if Warner-Lambert enters into a transaction
 with a third party ONLY "IF SUCH THIRD PARTY IS THE ACQUIRING PARTY".
 These are the precise words of the contract that Pfizer signed and is now
 disregarding.

 In Warner-Lambert's merger of equals with AHP, Warner-Lambert shareholders
 will own approximately 50% of the combined company, Warner-Lambert
 directors will be 50% of the combined company's board, and Warner-Lambert's
 senior management will hold key positions within the new management team
 including the position of Chief Executive Officer.  The combined company's
 Chief Executive Officer will report to the combined company's Board, and
 the combined company's other senior officers will report to the combined
 company's Chief Executive Officer.  This is not an acquisition of
 Warner-Lambert, and AHP is not an "acquiring party".

 The counterclaim also sets forth that Pfizer breached the Lipitor(R)
 agreements by using confidential information for the purpose of deciding to
 make, and pricing, its bid.  Under the agreements, Pfizer cannot use
 confidential information "FOR ANY PURPOSE OTHER THAN IN PERFORMANCE OF [THE
 LIPITOR(R)] AGREEMENT[S]".  This misuse of confidential information is
 another independent ground entitling Warner-Lambert to terminate the
 Lipitor(R) agreements, the Company said.  Under the agreements, the
 restriction on the use of confidential information would not end with a
 termination of the standstill.

 Mr. de Vink said, "If the court upholds our position that Warner-Lambert is
 entitled to terminate the Lipitor(R) relationship as a result of these
 breaches, there is no doubt that very substantial value will accrue to
 Warner-Lambert shareholders.  In that regard, before asserting this
 counterclaim, we satisfied ourselves that the marketing of Lipitor(R) would
 not suffer. Internally, and together with consultants and agencies,
 Warner-Lambert has already started detailed planning to be prepared to take
 over sole promotion of Lipitor(R), including all field-, office- and
 R&D-based programs.  These activities have already begun with respect to
 all major territories of the world."

 Pending a determination by the court, the Lipitor(R) agreements continue in
 effect.  However, if the court rules in Warner-Lambert's favor, upon
 termination, Warner-Lambert would have no obligation to make payments to,
 or share revenues with, Pfizer with respect to Lipitor(R).  A termination
 would not terminate the standstill agreements.

 Warner-Lambert said that the objective of its counterclaim is to create
 value for the Warner-Lambert shareholders.  It added that it has not sought
 an injunction against Pfizer making any offers.

 Warner-Lambert is a global company devoted to discovering, developing,
 manufacturing and marketing quality pharmaceutical, consumer health care,
 and confectionery products.  Its central research focus is on heart
 disease, diabetes, disorders of the central nervous system and women's
 health care.  In 1999, its revenues are expected to exceed $12 billion and
 the company will invest more than $1.2 billion in research and development.
 It employs more than 43,000 people worldwide.

 Statements made in this press release that state "we will," "we expect," or
 otherwise state Warner-Lambert's predictions for the future are
 forward-looking statements.  Actual results might differ materially from
 those projected in the forward-looking statements.  Additional information
 concerning factors that could cause actual results to materially differ
 from those in the forward-looking statements is contained in
 Warner-Lambert's annual report on Form 10K-A for the year ended December
 31, 1998 filed with the U.S. Securities and Exchange Commission.